[go: up one dir, main page]

WO2000051578A3 - Utilisation de ceramides pour le traitement de la mucoviscidose - Google Patents

Utilisation de ceramides pour le traitement de la mucoviscidose Download PDF

Info

Publication number
WO2000051578A3
WO2000051578A3 PCT/EP2000/001682 EP0001682W WO0051578A3 WO 2000051578 A3 WO2000051578 A3 WO 2000051578A3 EP 0001682 W EP0001682 W EP 0001682W WO 0051578 A3 WO0051578 A3 WO 0051578A3
Authority
WO
WIPO (PCT)
Prior art keywords
ceramides
treatment
cystic fibrosis
substances
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/001682
Other languages
German (de)
English (en)
Other versions
WO2000051578A2 (fr
Inventor
Florian Lang
Erich Gulbins
Lepple-Wienhues
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEPPLE WIENHUES
Original Assignee
LEPPLE WIENHUES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEPPLE WIENHUES filed Critical LEPPLE WIENHUES
Priority to AU31613/00A priority Critical patent/AU3161300A/en
Priority to EP00909267A priority patent/EP1156854A2/fr
Priority to CA002365290A priority patent/CA2365290A1/fr
Publication of WO2000051578A2 publication Critical patent/WO2000051578A2/fr
Publication of WO2000051578A3 publication Critical patent/WO2000051578A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne l'utilisation de céramides et/ou de substances contenant des céramides comme élément constitutif, et destinés au traitement de la mucoviscidose. Ces céramides sont notamment des céramides C2 et/ou C6. L'invention concerne également l'utilisation des substances susmentionnées pour traiter des maladies en liaison avec une régulation perturbée des processus de transport au niveau des membranes.
PCT/EP2000/001682 1999-03-03 2000-02-29 Utilisation de ceramides pour le traitement de la mucoviscidose Ceased WO2000051578A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU31613/00A AU3161300A (en) 1999-03-03 2000-02-29 Use of ceramides for the treatment of cystic fibrosis
EP00909267A EP1156854A2 (fr) 1999-03-03 2000-02-29 Utilisation de ceramides pour le traitement de la mucoviscidose
CA002365290A CA2365290A1 (fr) 1999-03-03 2000-02-29 Utilisation de ceramides pour le traitement de la mucoviscidose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19909115A DE19909115A1 (de) 1999-03-03 1999-03-03 Verwendung von Ceramiden zur Behandlung cystischer Fibrose
DE19909115.3 1999-03-03

Publications (2)

Publication Number Publication Date
WO2000051578A2 WO2000051578A2 (fr) 2000-09-08
WO2000051578A3 true WO2000051578A3 (fr) 2001-01-04

Family

ID=7899443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001682 Ceased WO2000051578A2 (fr) 1999-03-03 2000-02-29 Utilisation de ceramides pour le traitement de la mucoviscidose

Country Status (5)

Country Link
EP (1) EP1156854A2 (fr)
AU (1) AU3161300A (fr)
CA (1) CA2365290A1 (fr)
DE (1) DE19909115A1 (fr)
WO (1) WO2000051578A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084657A1 (fr) * 2004-03-02 2005-09-15 Mcgill University Compositions et methodes pour prevenir ou pour traiter une reaction inflammatoire

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074251A1 (fr) * 1981-09-04 1983-03-16 Yeda Research And Development Company, Ltd. Nouvelle fraction de lipides, sa préparation et compositions pharmaceutiques la contenant
WO1985003638A1 (fr) * 1984-02-23 1985-08-29 Yeda Research And Development Ltd. Compositions contenant des lipides actifs
US4766111A (en) * 1985-10-31 1988-08-23 Trustees Of Boston University Lipids with plasmin inhibitory properties
EP0450991A2 (fr) * 1990-02-20 1991-10-09 Synthelabo Utilisation de phosphatidylglycérol(diC 18:10)dans le traitement des maladies obstructives des voies aériennes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819870A1 (de) * 1987-06-12 1988-12-29 Hoerrmann Wilhelm Arzneimittel auf der basis von fett-amino-alkoholen
EP1179340A3 (fr) * 1994-09-30 2003-05-07 INEX Pharmaceutical Corp. Compositions d' introduction de substances polyanioniques dans des cellules
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074251A1 (fr) * 1981-09-04 1983-03-16 Yeda Research And Development Company, Ltd. Nouvelle fraction de lipides, sa préparation et compositions pharmaceutiques la contenant
WO1985003638A1 (fr) * 1984-02-23 1985-08-29 Yeda Research And Development Ltd. Compositions contenant des lipides actifs
US4766111A (en) * 1985-10-31 1988-08-23 Trustees Of Boston University Lipids with plasmin inhibitory properties
EP0450991A2 (fr) * 1990-02-20 1991-10-09 Synthelabo Utilisation de phosphatidylglycérol(diC 18:10)dans le traitement des maladies obstructives des voies aériennes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURDGE G C ET AL: "PLASMA LIPID CONCENTRATIONS IN CHILDREN WITH CYSTIC FIBROSIS: THE VALUE OF A HIGH-FAT DIET AND PANCREATIC SUPPLEMENTATION", BRITISH JOURNAL OF NUTRITION,CAMBRIDGE,GB, vol. 71, no. 6, June 1994 (1994-06-01), pages 959 - 964, XP000951637 *
GIROD S ET AL: "PHOSPHOLIPID COMPOSITION AND SURFACE-ACTIVE PROPERTIES OF TRACHEOBRONCIAL SECRETIONS FROM PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASES", PEDIATRIC PULMONOLOGY,JOHN WILEY, NEW YORK, NY,US, vol. 13, no. 1, May 1992 (1992-05-01), pages 22 - 27, XP000952015, ISSN: 8755-6863 *
GRIESE M ET AL: "PULMONARY SURFACTANT IN CYSTIC FIBROSIS", EUROPEAN RESPIRATORY JOURNAL,DK,MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, vol. 10, no. 9, September 1997 (1997-09-01), pages 1983 - 1988, XP000891384, ISSN: 0903-1936 *
KUIJCK VAN M A ET AL: "MOLECULAR CLONING AND EXPRESSION OF A CYCLIC AMP-ACTIVATED CHLORIDECONDUCTANCE REGULATOR: A NOVEL ATP-BINDING CASSETTE TRANSPORTER", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 93, no. 11, May 1996 (1996-05-01), pages 5401 - 5406, XP000946726, ISSN: 0027-8424 *
SZABO I ET AL: "TYROSINE KINASE-DEPENDENT ACTIVATION OF A CHLORIDE CHANNEL IN CD95-INDUCED APOPTOSIS IN T LYMPHOCYTES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 95, no. 11, 26 May 1998 (1998-05-26), pages 6169 - 6174, XP000946287, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2365290A1 (fr) 2000-09-08
DE19909115A1 (de) 2000-09-07
AU3161300A (en) 2000-09-21
EP1156854A2 (fr) 2001-11-28
WO2000051578A2 (fr) 2000-09-08

Similar Documents

Publication Publication Date Title
WO2001002992A8 (fr) Systeme et procede d'extension du regime d'achats groupes dans internet
AU2001262723A1 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
AU3015797A (en) Treated titanium dioxide
EP1183011A4 (fr) Methode, compositions pharmaceutiques et trousse de traitement de l'angine et/ou d'equivalents angineux
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU2002213887A1 (en) Process for the antimicrobial treatment of fiber materials
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU5038299A (en) Process for the biocidal treatment of surfaces
AU2001260834A1 (en) The treatment of herpes
AU2001293891A1 (en) New combination for the treatment of asthma
AU4774697A (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis
AU2021601A (en) Composition for the treatment of dandruff
WO2000051578A3 (fr) Utilisation de ceramides pour le traitement de la mucoviscidose
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU3059795A (en) Cosmetic composition which prevents or attenuates the photo-reactivity of titanium dioxide nanopigments
DE69812861D1 (de) Walzwerk zur herstellung von axialsymmetrischen teilen
AU7756900A (en) Treatment of chemical hydrolysates
FI971370A0 (fi) Menetelmä titaanidioksidin valmistamiseksi
AU2001286489A1 (en) Process for the purification of iosoctane and/or diisobutylene
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU2482101A (en) Process for the chlorination of hydrocarbons
WO1999025327A3 (fr) Intervention de petites molecules dans la replication du vih-1
AU1341895A (en) A biocide composition for the treatment of timber

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2365290

Country of ref document: CA

Ref country code: CA

Ref document number: 2365290

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000909267

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000909267

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09914594

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000909267

Country of ref document: EP